ArticleClinical and translational gastroenterology2026
Body Mass Index-Dependent Effect of Glucagon-Like Peptide 1 Receptor Agonist Therapy on Bowel Preparation Quality.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucagon-like peptide-1 receptor agonist (GLP-1RA) therapy has been associated with inadequate bowel preparation (IBP) during colonoscopy, but the role of baseline body mass index (BMI) remains unclear. We aim to assess whether baseline BMI modifies the association between GLP-1RA use and bowel preparation adequacy and lesion detection, hypothesizing a BMI-dependent effect modification.
methodsWe conducted a retrospective cohort study of 51,268 patients (46,883 controls, 4,385 GLP-1RA treated) undergoing colonoscopy. Patients were grouped by BMI category from normal or overweight to class III obesity. Multivariable logistic regression models incorporating treatment × BMI interaction terms were used to formally test for effect modification. Primary outcomes were IBP, adenoma detection, and sessile serrated polyp detection. Analysis was adjusted for age, sex, race, diabetes, and gastrointestinal medications.
resultsGLP-1RA use demonstrated significant BMI-dependent effect modification for IBP (global likelihood ratio test P = 0.001). In normal or overweight patients, GLP-1RA therapy was associated with increased odds of IBP (odds ratio 1.66; 95% confidence interval 1.37-2.02; P < 0.001). This effect progressively attenuated with increasing BMI and was negligible in class III obesity. GLP-1RA therapy did not demonstrate an additional adverse impact on adenoma or sessile serrated polyp detection rates compared with patients in similar BMI categories not receiving the therapy. DISCUSSION: GLP-1RA therapy increased IBP risk primarily in normal and overweight patients, with minimal effect in severe obesity. BMI stratification may inform personalized colonoscopy preparation strategies in GLP-1RA-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.